 |
|
The Effectiveness of Screening for Prostate Cancer
A Nested Case-Control Study
John Concato, MD, MPH;
Carolyn K. Wells, MPH;
Ralph I. Horwitz, MD;
David Penson, MD;
Graeme Fincke, MD;
Dan R. Berlowitz, MD, MPH;
Gregory Froehlich, MD;
Dawna Blake, MD;
Martyn A. Vickers, MD;
Gerald A. Gehr, MD;
Nabil H. Raheb, MD;
Gail Sullivan, MD, MPH;
Peter Peduzzi, PhD
Arch Intern Med. 2006;166:38-43.
Background Screening for prostate cancer is done commonly in clinical practice, using prostate-specific antigen (PSA) tests or digital rectal examination (DRE). Evidence is lacking, however, to confirm a survival benefit among screened patients. We evaluated the effectiveness of PSA, with or without DRE, in reducing mortality.
Methods We conducted a multicenter nested case-control study at 10 Veterans Affairs medical centers in New England. Among 71 661 patients receiving ambulatory care between 1989 and 1990, 501 case patients were identified as men who were diagnosed as having adenocarcinoma of the prostate from 1991 through 1995 and who died sometime between 1991 and 1999. Control patients were men who were alive at the time the corresponding case patient had died, matched (1:1 ratio) for age and Veterans Affairs facility. The exposure variable (determined blind to case-control status) was whether PSA testing or DRE was performed for screening prior to the diagnosis of prostate cancer among case patients, with the same time interval for control patients. The association of screening and overall or cause-specific (prostate cancer) mortality was adjusted for race and comorbidity.
Results A benefit of screening was not found in our primary analysis assessing PSA screening and all-cause mortality (adjusted odds ratio, 1.08; 95% confidence interval, 0.71-1.64; P = .72), nor in a secondary analysis of PSA and/or DRE screening and cause-specific mortality (adjusted odds ratio, 1.13; 95% confidence interval, 0.63-2.06; P = .68).
Conclusions These results do not suggest that screening with PSA or DRE is effective in reducing mortality. Recommendations for obtaining "verbal informed consent" from men regarding such screening should continue.
Author Affiliations: Clinical Epidemiology Research Center and Cooperative Studies Program Coordinating Center, Department of Veterans Affairs Connecticut Healthcare System, West Haven Veterans Affairs Medical Center (VAMC), West Haven (Drs Concato and Peduzzi and Ms Wells); Department of Medicine, Yale University School of Medicine, New Haven, Conn (Drs Concato and Peduzzi and Ms Wells); Office of the Dean, Case Western Reserve School of Medicine, Cleveland, Ohio (Dr Horwitz); Section of Urology, University of Southern California Keck School of Medicine, Los Angeles (Dr Penson); Center for Health Quality, Outcomes, and Economic Research, Bedford, Mass (Drs Fincke and Berlowitz); Veterans Affairs Outcomes Research Group, White River Junction, Vt (Dr Froehlich); Providence Veterans Affairs Medical Center, Providence, RI (Dr Blake); Surgical Service, Togus VAMC, Togus, Me (Dr Vickers); Medical Service, Manchester VAMC, Manchester, NH (Dr Gehr); Surgical Service, Northampton VAMC, Leeds, Mass (Dr Raheb); VA Connecticut Healthcare System, Newington VAMC, Newington, Conn (Dr Sullivan).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
No One Dies From Prostate Cancer?
Diane Chau
Arch Intern Med. 2006;166(14):1525.
EXTRACT
| FULL TEXT
No One Dies From Prostate Cancer?—Reply
John Concato and Carolyn K. Wells
Arch Intern Med. 2006;166(14):1526.
EXTRACT
| FULL TEXT
RELATED ARTICLE
The PSA Conundrum
Michael J. Barry
Arch Intern Med. 2006;166(1):7-8.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Public Knowledge of Benefits of Breast and Prostate Cancer Screening in Europe
Gigerenzer et al.
JNCI J Natl Cancer Inst 2009;101:1216-1220.
ABSTRACT
| FULL TEXT
Screening for Prostate Cancer
Brawley et al.
CA Cancer J Clin 2009;59:264-273.
ABSTRACT
| FULL TEXT
The Japanese Guideline for Prostate Cancer Screening
Hamashima et al.
Jpn J Clin Oncol 2009;39:339-351.
ABSTRACT
| FULL TEXT
Molecular Markers and Death From Prostate Cancer
Concato et al.
ANN INTERN MED 2009;150:595-603.
ABSTRACT
| FULL TEXT
Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
Lin et al.
ANN INTERN MED 2008;149:192-199.
ABSTRACT
| FULL TEXT
An Object Lesson: Source Determines the Relations That Trait Anxiety, Prostate Cancer Worry, and Screening Fear Hold with Prostate Screening Frequency
Consedine et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1631-1639.
ABSTRACT
| FULL TEXT
'A matter of faith, not science': analysis of media coverage of prostate cancer screening in Australian news media 2003-2006
MacKenzie et al.
JRSM 2007;100:513-521.
ABSTRACT
| FULL TEXT
Case 18-2007 -- A 54-Year-Old Man with Early-Stage Prostate Cancer
Kaufman et al.
NEJM 2007;356:2515-2520.
FULL TEXT
Screening for Cancer with PET and PET/CT: Potential and Limitations
Schoder and Gonen
JNM 2007;48:4S-18S.
ABSTRACT
| FULL TEXT
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
Miller et al.
JNCI J Natl Cancer Inst 2006;98:1134-1141.
ABSTRACT
| FULL TEXT
No One Dies From Prostate Cancer?--Reply
Concato and Wells
Arch Intern Med 2006;166:1526-1526.
FULL TEXT
No one dies from prostate cancer?
Chau
Arch Intern Med 2006;166:1525-1525.
FULL TEXT
Prostate Cancer Screening: Still Waiting for a Randomized Controlled Trial
JWatch General 2006;2006:5-5.
FULL TEXT
The PSA Conundrum
Barry
Arch Intern Med 2006;166:7-8.
FULL TEXT
|
